<bill session="117" type="s" number="1425" updated="2023-01-11T13:49:07Z">
  <state datetime="2021-07-29">REPORTED</state>
  <status>
    <unknown datetime="2021-07-29"/>
  </status>
  <introduced datetime="2021-04-28"/>
  <titles>
    <title type="display">Stop STALLING Act</title>
    <title type="official" as="introduced">A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.</title>
    <title type="short" as="reported to senate">Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act</title>
    <title type="short" as="reported to senate">Stop STALLING Act</title>
    <title type="short" as="introduced">Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act</title>
    <title type="short" as="introduced">Stop STALLING Act</title>
  </titles>
  <sponsor bioguide_id="K000367"/>
  <cosponsors>
    <cosponsor bioguide_id="B001277" joined="2021-04-28"/>
    <cosponsor bioguide_id="B001288" joined="2021-08-10"/>
    <cosponsor bioguide_id="B001310" joined="2021-10-07"/>
    <cosponsor bioguide_id="C001098" joined="2021-08-10"/>
    <cosponsor bioguide_id="D000563" joined="2021-08-10"/>
    <cosponsor bioguide_id="E000295" joined="2021-04-28"/>
    <cosponsor bioguide_id="G000386" joined="2021-04-28"/>
    <cosponsor bioguide_id="L000174" joined="2021-04-28"/>
    <cosponsor bioguide_id="O000174" joined="2021-08-10"/>
  </cosponsors>
  <actions>
    <action datetime="2021-04-28">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-04-28" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
    </action>
    <action datetime="2021-07-29" state="REPORTED">
      <text>Committee on the Judiciary. Ordered to be reported without amendment favorably.</text>
    </action>
    <action datetime="2021-12-08">
      <text>Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.</text>
    </action>
    <calendar datetime="2021-12-08" calendar="Senate Legislative" under="General Orders" number="179">
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.</text>
    </calendar>
  </actions>
  <committees>
    <committee code="SSJU" name="Senate Judiciary" subcommittee="" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="2883" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Business ethics"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
    <term name="Public participation and lobbying"/>
  </subjects>
  <amendments/>
  <summary date="2022-01-10T11:32:55Z" status="Reported to Senate">Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.</summary>
</bill>
